Minzasolmin

Minzasolmin (UCB0599; (R) -NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models[1][2].

Product Specifications

CAS Number

[1802518-92-8]

Product Name Alternative

UCB0599; (R) -NPT200-11

UNSPSC

12352005

Target

α-synuclein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/minzasolmin.html

Purity

98.60

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CN=C(N2CCN(CC2)C)S1)N[C@H](CCCC)CC3=CNC4=CC=CC=C34

Molecular Formula

C23H31N5OS

Molecular Weight

425.59

References & Citations

[1]Steiner MA. Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease. NPJ Parkinsons Dis. 2024 Mar 14;10 (1) :59.|[2]Baggett, et al. Novel Approaches Targeting in α-Synuclein for Parkinson's Disease: Current Progress and Future Directions for the Disease-Modifying Therapies. Brain Disorders (2024) : 100163.